Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure with Preserved Ejection Fraction

Circulation: Heart Failure

Volumn 9, Issue 11, 2016, Pages

  Valero Munoz, Maria ^a   Li, Shanpeng ^a   Wilson, Richard M ^a   Boldbaatar, Batbold ^a   Iglarz, Marc ^a,c   Sam, Flora ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cardiovascular Section   (United States)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

endothelin receptor antagonists; Endothelin 1; heart failure, diastolic; hypertrophy, left ventricular; myocytes, cardiac

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; CONNECTIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MACITENTAN; MYOCYTE ENHANCER FACTOR 2; TITIN N2B; UNCLASSIFIED DRUG; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; MESSENGER RNA; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TTN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THICKNESS; AGED; ANIMAL; BLOOD; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; DIASTOLE; DRUG EFFECTS; ECHOCARDIOGRAPHY; FEMALE; GENETICS; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HYPERTROPHY; HYPERTROPHY, LEFT VENTRICULAR; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ANIMALS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; CONNECTIN; DIASTOLE; ECHOCARDIOGRAPHY; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN B RECEPTOR ANTAGONISTS; ENDOTHELIN-1; FEMALE; HEART; HEART FAILURE; HUMANS; HYPERTROPHY; HYPERTROPHY, LEFT VENTRICULAR; IN VITRO TECHNIQUES; MALE; MEF2 TRANSCRIPTION FACTORS; MICE; MIDDLE AGED; MYOCYTES, CARDIAC; PYRIMIDINES; RNA, MESSENGER; STROKE VOLUME; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84995803461     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003381     Document Type: Article

References (35)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847. doi: 10.1093/eurheartj/ehs104.
2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679. doi: 10.1093/eurheartj/ehq426.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852. doi: 10.1161/CIR.0b013e31829e8807.
4. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016;133:e38-e360. doi: 10.1161/CIR.0000000000000350.
5. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247-1259. doi: 10.1161/CIRCULATIONAHA.114.013215.
6. Hamdani N, Paulus WJ. Myocardial titin and collagen in cardiac diastolic dysfunction: partners in crime. Circulation. 2013;128:5-8. doi: 10.1161/CIRCULATIONAHA.113.003437.
7. Wilson RM, De Silva DS, Sato K, Izumiya Y, Sam F. Effects of fixeddose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension. 2009;54:583-590. doi: 10.1161/HYPERTENSIONAHA.109.134932.
8. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374-1379.
9. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011;91:1-77. doi: 10.1152/physrev.00060.2009.
10. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett. 1993;332:31-34.
11. Sam F, Duhaney TA, Sato K, Wilson RM, Ohashi K, Sono-Romanelli S, Higuchi A, De Silva DS, Qin F, Walsh K, Ouchi N. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology. 2010;151:322-331. doi: 10.1210/en.2009-0806.
12. Tanaka K, Wilson RM, Essick EE, Duffen JL, Scherer PE, Ouchi N, Sam F. Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:976-985. doi: 10.1161/CIRCHEARTFAILURE.114.001279.
13. Valero-Munõz M, Li S, Wilson RM, Hulsmans M, Aprahamian T, Fuster JJ, Nahrendorf M, Scherer PE, Sam F. Heart failure with preserved ejection fraction induces beiging in adipose tissue. Circ Heart Fail. 2016;9:e002724. doi: 10.1161/CIRCHEARTFAILURE.115.002724.
14. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA, Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46:555-561. doi: 10.1161/01.HYP.0000176236.55322.18.
15. Essick EE, Ouchi N, Wilson RM, Ohashi K, Ghobrial J, Shibata R, Pimentel DR, Sam F. Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol. 2011;301:H984-H993. doi: 10.1152/ajpheart.00428.2011.
16. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207. doi: 10.1016/j.jacc.2006.08.050.
17. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452-3462. doi: 10.1093/eurheartj/ehu193.
18. Doi T, Sakoda T, Akagami T, Naka T, Mori Y, Tsujino T, Masuyama T, Ohyanagi M. Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2008;295:H1279-H1287. doi: 10.1152/ajpheart.00148.2008.
19. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64:541-549. doi: 10.1016/j.jacc.2014.05.030.
20. Zile MR, Bourge RC, Redfield MM, Zhou D, Baicu CF, Little WC. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2014;2:123-130. doi: 10.1016/j.jchf.2013.12.002.
21. Mulder P, Richard V, Bouchart F, Derumeaux G, Münter K, Thuillez C. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res. 1998;39:600-608.
22. Garcia AG, Wilson RM, Heo J, Murthy NR, Baid S, Ouchi N, Sam F. Interferon-? ablation exacerbates myocardial hypertrophy in diastolic heart failure. Am J Physiol Heart Circ Physiol. 2012;303:H587-H596. doi: 10.1152/ajpheart.00298.2012.
23. Rothermund L, Vetter R, Dieterich M, Kossmehl P, Gögebakan O, Yagil C, Yagil Y, Kreutz R. Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension. Circulation. 2002;106:2305-2308.
24. Pikkarainen S, Tokola H, Kerkelä R, Ilves M, Mäkinen M, Orzechowski HD, Paul M, Vuolteenaho O, Ruskoaho H. Inverse regulation of preproendothelin-1 and endothelin-converting enzyme-1beta genes in cardiac cells by mechanical load. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1639-R1645. doi: 10.1152/ajpregu.00559.2005.
25. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 1996;271:3221-3228.
26. Letizia C, De Toma G, Cerci S, Scuro L, De Ciocchis A, D'Ambrosio C, Massa R, Cavallaro A, Scavo D. Plasma endothelin-1 levels in patients with aldosterone-producing adenoma and pheochromocytoma. Clin Exp Hypertens. 1996;18:921-931.
27. Sütsch G, Bertel O, Rickenbacher P, Clozel M, Yandle TG, Nicholls MG, Kiowski W. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol. 2000;85:973-976.
28. Drawnel FM, Archer CR, Roderick HL. The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol. 2013;168:296-317. doi: 10.1111/j.1476-5381.2012.02195.
29. Collier P, Watson CJ, van Es MH, Phelan D, McGorrian C, Tolan M, Ledwidge MT, McDonald KM, Baugh JA. Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype. J Mol Cell Cardiol. 2012;52:148-153. doi: 10.1016/j.yjmcc.2011.10.002.
30. Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014;114:1052-1068. doi: 10.1161/CIRCRESAHA.114.301286.
31. Xu SW, Howat SL, Renzoni EA, Holmes A, Pearson JD, Dashwood MR, Bou-Gharios G, Denton CP, du Bois RM, Black CM, Leask A, Abraham DJ. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem. 2004;279:23098-23103. doi: 10.1074/jbc.M311430200.
32. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004;15:2707-2719. doi: 10.1091/mbc.E03-12-0902.
33. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol. 2000;32:2151-2162. doi: 10.1006/jmcc.2000.1281.
34. Barron AJ, Hughes AD, Sharp A, Baksi AJ, Surendran P, Jabbour RJ, Stanton A, Poulter N, Fitzgerald D, Sever P, O'Brien E, Thom S, Mayet J; ASCOT Investigators. Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy. Hypertension. 2014;63:252-258. doi: 10.1161/HYPERTENSIONAHA.113.01360.
35. Zakeri R, Borlaug BA, McNulty SE, Mohammed SF, Lewis GD, Semigran MJ, Deswal A, LeWinter M, Hernandez AF, Braunwald E, Redfield MM. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail. 2014;7:123-130. doi: 10.1161/CIRCHEARTFAILURE.113.000568.